Platelets and Plasma Lipids Relationship as a Biomarker and Potential Therapeutic Target of Thrombogenesis

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40+
SponsorUniversity of Sao Paulo

About this trial

The objective of this clinical trial is to compare the effect of two different lipid emulsion formulations versus no emulsion on platelet aggregation in individuals without a history of ischemic disease. The hypothesis of this study is:

Platelet aggregation is inversely associated with higher plasma lipid concentrations.

The researchers will compare platelet aggregation in the presence and absence of lipid nanoemulsions in vitro through three pathways using the agonists collagen, adenosine diphosphate, and arachidonic acid. The tests will be performed using light-transmission aggregometry. Various participant parameters, such as lipid profile, will be evaluated to analyze possible correlations with the observed results.

Participants must:

Meet the study's inclusion criteria; Sign the informed consent form; Report to the blood draw laboratory at InCor's AB on the scheduled date and time after fasting for at least 8 hours.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Men and women aged ≥ 40 years.

Willingness to sign the informed consent form.

Absence of known atherosclerotic disease

Disqualifiers

Use of antiplatelet agents.

Use of anticoagulants.

Use of lipid-lowering agents.

Use of oral hypoglycemic agents or insulin.

Trial population

Eligible individuals satisfying the standard wellness criteria.

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

45 Participants
are grouped into 2 trial groups
Group A: Control group
Group B: Case group

Trial outcomes

Primary outcomes

1

Effect of Lipid Emulsions on Platelet Aggregation Assessed by Optical Aggregometry

Comparison of the effect of different lipid emulsion formulations versus no emulsion (control) on platelet aggregation in blood samples from individuals without a history of ischemic disease.

Time frame
Day 1 (single blood sample collection)

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.